Xiromed LLC today announced the launch of Testosterone Gel 1.62% Metered Dose Pump (20.25mg/1.25g pump actuation), an AB-rated generic version of AndroGel® 1.62%.  

AndroGel® 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.  Annual market sales for AndroGel® 1.62% and its generic equivalents for the twelve month period ending June, 2020 were $135 million, according to IQVIA™.    

Xiromed CEO, Narasimhan Mani commented, “This launch demonstrates Xiromed’s commitment to bringing a diversified portfolio of high quality generic products to the US market.  Xiromed has a strong foundation in hormonal products, and this launch further establishes the ongoing evolution of our pipeline into a broad range of dosage forms and technologies.”

Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain.  Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market.  In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products.  Learn more at http://www.xiromed.com/usa/